ECC5004 (AZD5004) Tracker
AstraZeneca’s oral GLP-1 — and your protocol today
ECC5004 — also known as AZD5004 — is a once-daily oral small-molecule GLP-1 receptor agonist developed by Eccogene and AstraZeneca. It is investigational and not FDA approved. Shotlee is the free app to track your current protocol while the oral GLP-1 field develops.
What is ECC5004 (AZD5004)?
ECC5004 (AZD5004) is a once-daily oral small-molecule GLP-1 receptor agonist originated by Eccogene and being developed with AstraZeneca. Small-molecule oral agonists aim to deliver GLP-1 weight loss in a daily tablet without injections.
It is one of several oral GLP-1 candidates racing toward market alongside Lilly’s orforglipron (Foundayo), Structure Therapeutics’ aleniglipron (GSBR-1290), and Roche’s CT-996. AstraZeneca’s broader obesity push (including a major licensing deal) has put extra attention on this program.
ECC5004 Key Facts
What to Track in Shotlee
Build clean baseline data now so you can compare if oral GLP-1s reach the market.
Oral GLP-1 Development Outlook
Protocol FAQs
ECC5004 (also AZD5004) is a once-daily oral small-molecule GLP-1 receptor agonist from Eccogene and AstraZeneca, in clinical development for weight loss and type 2 diabetes. It is investigational and not FDA approved.
Yes. ECC5004 is Eccogene’s development code and AZD5004 is AstraZeneca’s code for the same oral GLP-1 molecule being co-developed.
Both are once-daily oral small-molecule GLP-1 agonists but are different molecules from different companies (AstraZeneca/Eccogene vs Eli Lilly). They are competing oral GLP-1 candidates; no head-to-head data exists.
It is investigational and only available in trials. Timing depends on later-stage results and regulatory review. Follow Shotlee’s tracker pages for updates.
Yes. Shotlee logs doses, weight, side effects, and labs for your current medication for free, so you have a clean baseline if oral GLP-1s like ECC5004 launch.
Track Your Protocol in Shotlee
Free dose logs, weight trends, and side effect tracking — ready for the oral GLP-1 wave.